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Abstract Healthy human heart rate fluctuates overtime show-
ing long-range fractal correlations. In contrast, various cardiac
diseases and normal aging show the breakdown of fractal
complexity. Recently, it was shown that human induced plu-
ripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in-
trinsically exhibit fractal behavior as in humans. Here, we
investigated the fractal complexity of hiPSC-derived long
QT-cardiomyocytes (LQT-CMs). We recorded extracellular
field potentials from hiPSC-CMs at baseline and under the
effect of various compounds including β-blocker bisoprolol,
ML277, a specific and potent IKs current activator, as well as
JNJ303, a specific IKs blocker. From the peak-to-peak-inter-
vals, we determined the long-range fractal correlations by
using detrended fluctuation analysis. Electrophysiologically,
the baseline corrected field potential durations (cFPDs) were
more prolonged in LQT-CMs than in wildtype (WT)-CMs.
Bisoprolol did not have significant effects to the cFPD in
any CMs. ML277 shortened cFPD in a dose-dependent fash-
ion by 11 % and 5–11 % in WT- and LQT-CMs, respectively.
JNJ303 prolonged cFPD in a dose-dependent fashion by 22%
and 7–13 % in WT- and LQT-CMs, respectively. At baseline,
all CMs showed fractal correlations as determined by short-
term scaling exponent α. However, in all CMs, the α was
increased when pharmacological compounds were applied in-
dicating of breakdown of fractal complexity. These findings
suggest that the intrinsic mechanisms contributing to the frac-
tal complexity are not altered in LQT-CMs. The modulation of
IKs channel and β1-adrenoreceptors by pharmacological com-
pounds may affect the fractal complexity of the hiPSC-CMs.
Keywords Induced pluripotent stem cell . LongQT
syndrome . Cardiomyocytes . Multielectrode array .
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Introduction
Heart rate dynamics have been previously analyzed using
conventional linear and newer nonlinear methods in healthy
and diseased states (for review see Perkiömäki [1]). The non-
linear indices of the RR variations include fractals, which are
geometrically defined as objects composed of subunits (and
sub-subunits) that sustain self-similarity on different measure-
ment scales [2]. The characteristic feature of fractals is 1/f-like
fluctuations, which has been shown to be present in a healthy
human heartbeat [3–6]. Such fluctuations possess long-range
correlations indicative of a memory effect, which means that
the heart rate is not only related to immediately preceding
value but also to values in the remote past [2].
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In the heart rate time series, a breakdown of 1/f-like fluc-
tuations may lead into either completely uncorrelated random-
ness (white noise) or into total correlation resembling random
walk (Brownian motion). A number of studies have shown
that in various cardiac disease states (e.g. congestive heart
failure, myocardial infarction) the fractal 1/f-like long-range
correlations of the heartbeat breakdown producing more un-
correlated randomness [7–13]. Furthermore, normal aging has
been associated with the breakdown of fractal complexity
producing more total correlation in the heartbeat dynamics
[6, 14, 15]. Thus, it is thought that the breakdown of fractal
complexity in heart rate dynamics may cause the system to be
less adaptable and less responsive to unpredictable stimuli and
stresses increasing susceptibility to injury and illness [6, 16].
The biological origin of the fractal-like behavior has not
been yet fully established and is somewhat contradictory. In
the heart, the origin of the fractal-like behavior is thought to
result from complex interaction between vagal and sympathet-
ic inputs of the autonomous nervous system [17, 18].
Experimental observations in humans have supported this no-
tion [19–23], although opposing views have been presented
[24]. However, evidence suggests that monolayer cultures of
rat ventricular cardiomyocytes and human induced pluripotent
stem cell-derived cardiomyocytes (hiPSC-CMs) lacking auto-
nomic control exhibit fractal-like complexity, which indicates
that the autonomous nervous system input is not necessary for
fractal dynamics [25, 26]. It has been further demonstrated
that single cardiomyocytes also exhibit fractal-like complexity
and that intracellular Ca2+-cycling mechanisms contribute to
the fractal complexity of the single cardiomyocytes [27].
Long QT syndrome (LQTS) is a potentially severe life-
threatening arrhythmic cardiac disease characterized by
prolonged QT interval on the electrocardiogram. LQTS is asso-
ciatedwith torsades de pointes, a special type of ventricular tachy-
cardia, which may degenerate into ventricular fibrillation and
cause sudden cardiac death [28]. Inherited forms of LQTS are a
result of mutations in the cardiac ion channel coding genes. One
of the most common LQTS genes isKCNQ1, which encodes the
α-subunit of the voltage-gated potassium channel responsible for
the slow delayed rectifier K+ current (IKs) [29, 30]. In Finland, the
prevalence of gene mutations associated with LQTS is high
(0.4 % of Finnish population), which has been explained to be
caused by four founder mutations with one of them being C-
terminal G589D missense mutation in KCNQ1 gene [31, 32].
The hiPSCs represent excellent research tool to study the patho-
physiology of inherited cardiac diseases [33–41]. Until now, the
fractal dynamics of hiPSC-LQT-CMs have not been investigated.
Here, we utilize patient-specific LQTS disease model [41]
to study the fractal dynamics in the symptomatic and asymp-
tomatic LQTS type 1 (LQT1)-specific CMs carrying Finnish
founder mutation G589D. The aim of this study was to inves-
tigate the fractal dynamics of LQT-CMs in unmedicated and
medicated conditions as compared to healthy control and
under the effect of various compounds affecting cardiac
action potential.
Material & Methods
ECG Recordings and Human Induced Pluripotent Stem
Cell Generation
The study was approved by the ethical committee of
Pirkanmaa Hospital District (R08070). Participants who
volunteered for the study gave their consent. The ECGs were
recorded using MARS-Holter from a healthy individual,
asymptomatic LQT-mutation carrier and symptomatic LQT-
patient. The LQT-patients are on bisoprolol medication. The
healthy individual has no medication. Human iPSCs were
generated as described earlier [42]. The LQT1-specific
hiPSCs were derived from patients’ skin fibroblasts carrying
G589D missense mutation in KCNQ1 [41, 43].
Patient Characteristics
Skin biopsies with LQT1 mutation were obtained from a
symptomatic 41-year old female patient (QTc interval,
456 ms) and from an asymptomatic 28-year old female muta-
tion carrier (QTc interval, 428 ms). Both carry the KCNQ1
G589D mutation. The symptomatic 41-year old patient had
experienced seizures, episodes of unconsciousness and synco-
pe beforeβ-blocker (bisoprolol) medication. The healthy con-
trol human iPS cells were derived from skin fibroblasts of a
healthy 55-year old female (QTc interval, 406 ms) [44].
Human Induced Pluripotent Stem Cell Culture,
Differentiation and Characterization
Human iPS cells were cultured and differentiated as previous-
ly described [43]. All the hiPSC lines (UTA.04602.WT,
UTA.00208.LQT1, UTA.00211.LQT1, UTA.00303.LQT1
and UTA.00313.LQT1) and the differentiated CMs from them
have been previously characterized elsewhere [41, 43, 44].
Multielectrode Array Recordings and Data Analysis
In this study, 30–45 days old hiPSC-CMs were used for the
experiments. Spontaneously beating cardiomyocyte clusters
were manually dissected and plated on 6-well MEAs (6-well
MEA 200/30iR-Ti-tcr, Multichannel Systems, Reutlingen,
Germany), which were first coated with fetal bovine serum
(FBS, Invitrogen) for 30 min at room temperature and then
with 0.1 % gelatine (Sigma Aldrich) for 1 h at room temper-
ature. The cardiomyocyte clusters were cultured in EB-medi-
um: KO-DMEM with 20 % FBS, NEAA, Glutamax and pen-
icillin/streptomycin. The experiments were conducted in 5 %
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FBS containing EB-medium (5 % EB-medium). Before drug
tests, the field potentials originating from the spontaneously
beating cardiomyocytes were recorded for 30min (baseline) at
+37 °C with the MEA platform (MEA2100-2 × 60–2,
Multichannel Systems, Reutlingen, Germany) using 10 kHz
sampling frequency and MC_Rack (Multichannel Systems,
Reutlingen, Germany) software. After the 30-min baseline
measurement, the MEA plate was put on +37 °C thermal plate
(Tokai Hit, Japan) for keeping the temperature stable while
adding drugs. The following drugs were used in the study:
Bisoprolol (Sigma-Aldrich), ML277 (Tocris Bioscience) and
JNJ303 (Tocris Bioscience). The drugs were dissolved in di-
methyl sulfoxide (DMSO, Sigma-Aldrich) according to man-
ufacturer’s instructions. The bisoprolol concentrations were
chosen based on its therapeutic blood serum concentration
range [45]. For bisoprolol, 260 nM (upper limit of the thera-
peutic serum concentration) and 520 nM (twice the upper limit
of the therapeutic concentration) concentrations were used.
ML277 (IKs channel activator) concentrations of 1 μM and
2 μM were chosen based on previous reports [46, 47]. The
concentrations of IKs blocker JNJ303 (300 nM and 1000 nM)
were chosen based on our previous study [41]. After drug
addition, the MEA plates were incubated for 5 min at
+37 °C thermal plate before the 30-min measurement (first
drug concentration). After this, we added more drugs to the
cells (second drug concentration) and similarly as before, re-
corded the field potentials for 30 min. We also conducted
vehicle control experiments with similar protocol as described
above, with the exception that no drugs but only DMSO
(0.1 %) was added to the cells. The recording time for baseline
and for each drug concentration was 30 min. The data obtain-
ed from MEA was analyzed by our in-house developed
CardioMDA software, which averages field potential signals
using cross correlation algorithms [48]. From each recording,
the last 2 min from the 30-min recording were chosen for
averaging the field potential signals. For determining the field
potential duration (FPD), the onset was determined as the
beginning of depolarizing peak and the offset as Tmax of the
repolarizing wave. The Bazett’s and Fridericia’s formula were
used to calculate the corrected field potential duration (cFPD).
Detrended Fluctuation Analysis
We applied detrended fluctuation analysis (DFA) to the RR-
intervals. DFA is one of the most used time-series analysis
methods that gives a reliable estimate for the existence and
the characteristics of long-range correlations in the data [7].
DFA has been applied in various fields of science rang-
ing from physiological signals such as heartbeat and
gait [49] to, for example, musical rhythms [50, 51],
rainfall statistics [52], structural properties of DNA
[53], and electronic quantum transport [54].
A detailed description of DFA can be found in the above-
listed references and here we only summarize the main steps.
First, we take the peak-to-peak intervals of the hiPSC-CM or
ECG data set and subtract the mean value, so that we consider
the fluctuations around the mean. Next, we integrate the series
by taking a cumulative sum of the fluctuations. The time axis
is then divided into non-overlapping windows, and in each
window, a least-squares line (trend) is fit to the data. The
root-mean-square deviations from the trend (residuals) are av-
eraged through the whole data set. This procedure is repeated
for different window sizes. As a result, we get relationship
between the window size and the average fluctuation (within
that window size). The slope in this plot in a log-log scale
corresponds to the DFA exponent α. White noise with no
correlation between consecutive values has α = 0.5, whereas
Brownian motion with strongly correlated values generated
by uncorrelated consecutive increments has α = 1.5. In gen-
eral, intermediate predictability between these limits with
0.5 < α ≤ 1.5 indicates long-range (fractal) correlations.
Anti-correlations are characterized by −0.5 < α < 0.5. The
special case of pink noise α = 1 corresponds to 1/f behavior.
Statistical Analyses
FromMEA data, one-way ANOVA followed by Dunnet’s post
hoc test was performed to test differences in baseline values
between control and LQT cell lines (IBM version 22.0; SPSS
Inc., Chicago, USA). If datasets did not meet ANOVA require-
ments (normal distribution, equal variances), nonparametric test
Mann-Whitney U followed by alpha correction was employed
to compare control cell line and LQT cell lines. In drug exper-
iments, the baseline and the effect of drug concentrations were
compared using paired sample t-test. Similarly, if datasets did
not meet the requirements for t-test, nonparametric Wilcoxon
test was employed. From DFA data, paired sample t-test was
employed to determine the statistical differences between base-
line and each drug concentration. The p < 0.05 was considered
statistically significant. The levels of significance are represent-
ed as (*) p < 0.05, (**) p < 0.01 and (***) p < 0.001. The cFPD
prolongations of >10 % are considered physiologically signif-
icant. The data is presented as mean ± standard deviation (SD).
Results
The Effect of Pharmacological Compounds
to the hiPSC-CM Clusters
The 208.LQT1 and 211.LQT1 were derived from symptom-
atic patient whereas 303.LQT1 and 313.LQT1 were derived
from asymptomatic mutation carrier. The baseline cFPDs
(Fridericia’s correction) were significantly more prolonged
in hiPSC-LQT-CMs than in healthy WT-CMs (Fig. 1b, d, f).
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Similar results were obtained when Bazett’s FPD correction
was used (Supplemental Fig. 1). In contrast, we did not find
any significant differences in the beating rates (BRs) between
WT- and LQT-CMs (Fig. 1 a, c, e).
β-Blocker Bisoprolol The bisoprolol did not cause any major
differences in the BRs of the hiPSC-CMs (Fig. 1a). We noted a
slightly increasing trend of BR with increasing bisoprolol con-
centration in the hiPSC-CMs from asymptomatic mutation car-
rier (15 % for 303.LQT1 and 19 % for 313.LQT1). As for the
cFPD, bisoprolol caused only mild cFPD prolongation in the
WT-CMs (3–7 %) at the concentration range of 260–520 nM.
Similar cFPD prolongations were seen in LQT-CMs from
symptomatic patient (2–6 % for 208.LQT1 and 5–7 % for
211.LQT1) and from asymptomatic mutation carrier (5–10 %
for 303.LQT1 and 5–8 % for 313.LQT1) at the concentration
range of 260-520 nM (Fig. 1b). The representative bisoprolol
traces for WT- and LQT-CMs are illustrated in Fig. 2a.
IKs ActivatorML277 TheML277 caused significant increase
in the BRs of WTand 211.LQT1, 9 % and 14 %, respectively
(Fig. 1c). Overall, the trend of increasing BR with increasing
ML277 concentration was observed although statistical sig-
nificance was not found for all the cell lines. As expected, the
ML277 shortened the cFPD in a dose-dependent manner, al-
though the cFPD shortening was relatively mild (Fig. 1d). In
the WT, the shortening of cFPD was 11 % whereas in the
LQTs it ranged from 5 to 11 % at the concentration range of
1-2 μM. The representative ML277 traces for WT- and LQT-
CMs are illustrated in Fig. 2b.
IKs Blocker JNJ303 Blocking the IKs channel with JNJ303
did not significantly change the BRs of the WT- or LQT-CMs
except in 313.LQT1, in which the 23 % increase in the BR
was observed (Fig. 1e). JNJ303 showed a dose-dependent
cFPD prolongation in the WT- and LQT-CMs (Fig. 1f). The
most increment in cFPD was seen in the WT (22 %) whereas
in the LQTs, the cFPD increase was around 7–13 % at the
highest concentration (1000 nM). The representative JNJ303
traces for WT- and LQT-CMs are illustrated in Fig. 2c.
Detrended Fluctuation Analysis (DFA) of Healthy
Control- and LQT-Specific Cardiomyocytes and ECG
Data
We first determined the fractal scaling exponent α from hu-
man subjects who participated to the study (n = 3). Results are
shown in Table 1. Next, we determined the scaling exponentα
from hiPSC-CMs derived from the same human subjects par-
ticipating to the study. In Fig. 3 we show the DFA results of
the peak-to-peak fluctuations for healthy control- (WT) and
LQT-specific CMs when exposed to bisoprolol (Fig. 3 a),
Fig. 1 The effects of various compounds to the human induced
pluripotent stem cell (hiPSC)-derived cardiomyocytes’ field potential
parameters. The upper row depicts the beating rate (BR) and the lower
row Fridericia-corrected field potential duration (cFPD). The baseline
cFPDs of long QT-specific cardiomyocytes were significantly more
prolonged than in healthy wild type-cardiomyocytes. The asterisks on
top of the bars depict the statistical significance for mean BR or cFPD
change compared to baseline values. Significance levels are indicated by
(*) p < 0.05, (**) p < 0.01 and (***) p < 0.001, respectively
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ML277 (Fig. 3 b), or JNJ303 (Fig. 3c). The first bar in all the
subplots corresponds to the baseline with zero drug con-
centration. The LQT data is grouped according to symp-
tomatic (208.LQT1, 211.LQT1) and asymptomatic cases
(303.LQT1, 313.LQT1) shown in the middle and in the
right column, respectively.
We found that all the average baseline values for the DFA
scaling exponent are close to one, i.e., α ~ 0.9–1.1. There was
Fig. 2 The representative traces of the human induced pluripotent stem
cell (hiPSC)-derived wild type- and long QT (LQT)-specific
cardiomyocytes under the effect of various compounds. The LQTs are
grouped according to symptomatic (208.LQT1, 211.LQT1) and
asymptomatic cases (303.LQT1, 313.LQT1) shown in the middle and
in the right column, respectively. a) β-blocker Bisoprolol, b) IKs
activator ML277 c) IKs blocker JNJ303. Notice, how the Tmax of the
repolarization wave is relatively unchanged between baseline and
different bisoprolol concentrations depicting marginal effect of the β-
blocker to the corrected field potential duration (cFPD). However, IKs
activator ML277 shows clear shortening of cFPD seen by shift in the
Tmax. Similarly, but conversely to ML277, IKs blocker JNJ303 shows
clear prolongation of cFPD assessed by the shift in the Tmax
Table 1 The patient
characteristics and detrended
fluctuation analysis from ECG
data
Healthy individual LQT1-patient (symptomatic) LQT1-patient (asymptomatic)
Age 55 41 28
Medication - Bisoprolol Bisoprolol
QTc (ms) 406 456 428
α 1.21 ± 0.03 1.08 ± 0.02 1.07 ± 0.02
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no notable difference in the baseline α values between
the WT and the LQTs. This is in line with our ECG
data, which shows α of 1.08, 1.07 and 1.21 for symp-
tomatic and asymptomatic LQT patient as well as for
healthy individual, respectively (Table 1). However, all
the pharmacological compounds lead to an increase in
the DFA scaling exponent α toward Brownian motion
(α = 1.5) when compared to the baseline (Fig. 3). The
trend is visible both in the WT and in the LQTs. In
most cases a further increase in the concentration does
not affect α. When comparing all the α values of WT
and LQTs, we did not find any statistical difference
between the groups. We also conducted vehicle control
experiments in which no pharmacological compounds
but only DMSO (0.1 %) was added to the CMs. We
did not observe any significant changes in the α scaling ex-
ponent during these recordings. The α was 1.024 ± 0.13 at
baseline, 1.00 ± 0.12 (first DMSO addition) and 1.03 ± 0.13
(second DMSO addition) (n = 6). Thus, the change seen in α
scaling exponent with various pharmacological compounds
reflect the intrinsic properties of the pharmacological com-
pounds themselves.
Fig. 3 The detrended fluctuation analysis (DFA) α scaling exponents of
the human induced pluripotent stem cell (hiPSC)-derived wild type- and
long QT (LQT)-specific cardiomyocytes. The LQTs are grouped
according to symptomatic (208.LQT1, 211.LQT1) and asymptomatic
cases (303.LQT1, 313.LQT1) shown in the middle and in the right
column, respectively. a) (row) β-blocker Bisoprolol, b) IKs activator
ML277 c) IKs blocker JNJ303. At baseline, the α scaling exponents are
close to 1 in all hiPSC-CMs. The addition of various compounds to the
hiPSC-CMs increased the α scaling exponent closer to Brownian motion
(α = 1.5). The asterisks on top of the bars depict the statistical significance
for mean α scaling exponent change compared to baseline values.
Significance levels are indicated by (*) p < 0.05, (**) p < 0.01 and
(***) p < 0.001, respectively
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Discussion
In human hearts, the fractal dynamics is thought to result from
complex interaction between vagal and sympathetic inputs of
autonomous nervous system [17, 18]. However, evidence sug-
gest that the hiPSC-CMs also exhibit fractal-like complexity
indicating intrinsic mechanisms of the CMs contributing to
fractal dynamics [26, 27]. This study further supports the con-
cept that healthy hiPSC-CMs lacking autonomous nervous
system input exhibit fractal-like complexity at baseline condi-
tion. We also observed that the untreated (without any phar-
macological intervention) hiPSC-LQT-CMs also appear to ex-
hibit fractal-like complexity at baseline condition. This result
is in line with the previous study in untreated patients with
congenital LQTS [55]. Thus, our results further expand this
concept suggesting that the intrinsic mechanisms contributing
to the fractal-like complexity is not altered in hiPSC-LQT-
CMs.However, it is of note that the results obtainedwere from
2 LQTS patients only and further studies on a larger popula-
tion would be needed to definitely conclude the matter.
The Electrophysiological Properties of the hiPSC-CMs
The baseline behavior of hiPSC-CMs is in line with our pre-
vious studies [41, 43]. Results obtained from this study clearly
show that the cFPDs, corrected with either Bazett’s or
Fridericia’s formulae, are more prolonged in LQT-CMs than
in healthy WT-CMs. We also investigated the healthy and
LQT-specific hiPSC-CMs under the effect of β-blocker
bisoprolol and pharmacological compounds affecting specifi-
cally to cardiac ion channel IKs. Overall, the drug effects in
LQT-CMs appeared to be of similar magnitude to those of
WT-CMs, similar to our previous findings [43].
The Effect of Bisoprolol to the Fractal Complexity of
hiPSC-CMs The β-blockers are the standard and currently,
the only treatment of choice for LQTS patients [56]. Here, in
order for valid comparisons between cellular and whole heart
data, we chose to study bisoprolol in hiPSC-CMs because the
LQTS patients volunteered for this study were on bisoprolol
medication. Bisoprolol, a β1-adrenoreceptor selective β-
blocker, did not have physiological significance to the field
potential parameters (>10 % cFPD prolongation) in any of the
hiPSC-CMs at clinically relevant concentration. It is important
to notice that we did not activate β-receptors with β-agonists
prior to β-blocker application. However, the acute application
of bisoprolol increased the α scaling exponent toward
Brownian motion (α = 1.5) in all hiPSC-CMs at the upper
limit of therapeutic concentration (260 nM). At 520 nM, the
effect was attenuated. Although the baseline α data from
hiPSC-LQT-CMs correlated with the ECG data (α ~ 1.0),
bisoprolol α data did not correlate with the ECG data. The
discrepancy between cellular and heart α data remains yet
unclear but it may be attributed to e.g. acute application of
the bisoprolol or in the absence of autonomous nervous sys-
tem in hiPSC-LQT-CMs, whichmay affect to fractal complex-
ity upon drug application. Previous human study has shown
that the fractal complexity (α ~ 1.0) was unaltered in patients
with congenital LQTS treated or untreated with β-blockers
[55]. Thus, the β-blockers may not have significant effect on
the α of the whole LQTS hearts. On the other hand, there is
evidence from the human studies that the β-blocker treatment
improves fractal dynamics of the heart in advanced congestive
heart failure patients by increasing the α scaling exponent
during 1–3-month therapy period [21–23]. It is completely
unknown whether such differences result from the different
disease states, the type of β-blocker used or treatment periods
among other things. However, this study clearly shows that
although the field potential parameters were not significantly
changed, the intrinsic mechanisms contributing to fractal-like
complexity were altered during acute β-blocker treatment. On
the other hand, further studies would be needed to answer
what the effect would be in long-term (chronic) situation and
what the mechanism behind of this phenomenon is.
The significance of the fractal complexity resembling
Brownian motion in the heart is unclear. The loss of fractality
toward white noise (α = 0.5) has been found to predispose to
severe life-threatening arrhythmias and cardiac death [9, 10,
13]. However, very little is known when the fractal dynamics
of the heart become more correlated resembling Brownian
motion (α = 1.5). Such phenomenon has been observed in
healthy elderly subjects implying decrease of fractal complex-
ity with age [6, 14, 15] and, although not yet proven, it has
been suggested that such systemwould be more susceptible to
injury and illness in the elderly [6, 16].
The Effect of IKs Affecting Pharmacological Compounds
to the Fractal Complexity of hiPSC-CMs Next, we investi-
gated the effects of the other two pharmacological compounds
(ML277 and JNJ303) to hiPSC-CMs. The ion channel activa-
tor ML277 has been shown to augment specifically IKs current
and shorten the action potential duration in both healthy and
LQT-CMs [46, 47]. Similarly, in this study, the ML277 short-
ened the cFPD although the effect was relatively mild in these
hiPSC-CM clusters at 1-2 μMconcentration. Similarly, as was
seen with bisoprolol, also ML277 resulted in the dysfunction
of regulatory mechanisms contributing to fractal complexity
as the α scaling exponent was increased toward Brownian
motion in all hiPSC-CMs at 1 μM. However, at 2 μM a small
difference was seen that in the WT-CMs α exponent de-
creased to baseline level whereas the LQT-CMs α exponents
continued to increase from 1 μM, which was most prominent-
ly seen in CMs derived from symptomatic patient (208.LQT1
and 00,211.LQT1). Furthermore, the effect of JNJ303, a po-
tent and specific IKs blocker [57] known to evoke torsades de
pointes, was assessed in hiPSC-CMs. The WT-CMs appeared
to bemore sensitive to JNJ303 than LQT-CMs asmeasured by
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cFPD prolongation. This result is in line with our previous
findings from single WT- and LQT-CMs measured with patch
clamp using the same cell lines [41]. Although not yet proven
in the experimental setting, this indicates that the IKs current is
diminished in the LQT1-CMs harboring G589D missense
mutation compared to healthy WT-CMs. Contradictory to
our expectations, also the JNJ303 resulted in similar alter-
ations of fractal complexity in hiPSC-CMs as ML277 by in-
creasing the α scaling exponent. Taken together, these evi-
dence imply that the modulation of the ion channel generating
IKs current with pharmacological compounds may result in the
dysfunction of the intrinsic mechanisms contributing to fractal
complexity. Indeed, rhythmic ion channel activation and inac-
tivation in pacemaker cells has been thought to contribute to
the ultradian rhythmicity in addition to spontaneous Ca2+-cy-
cling [58]. Previous study has shown that the disruption of
intracellular Ca2+ handling causes alterations in the scaling
exponent α, mostly by decreasing it [27]. Here, we have
shown that at baseline, the rhythmicity of hiPSC-CMs is
sustained as determined by long-range fractal correlations.
Furthermore, the modulation of the ion channel generating
IKs current with specific pharmacological compounds disrupts
CM rhythmicity and fractal complexity.
Potential Limitation of the Study
In this study, only the acute effects of the various compounds
to the fractal-like complexity were assessed in hiPSC-CMs.
Further studies would be needed to show the chronic, long-
term effects of the compounds. Moreover, the mechanisms
behind the alterations in fractal complexity were not studied.
We did not investigate in detail the effect of β-adrenergic
agonist to the long-range fractal correlations of hiPSC-CMs.
Also, with this model we could not take into account the
continuous exposure of sympathetic and parasympathetic
stimuli affecting CMs in vivo. This study does not answer to
what would be the implications of altered fractality toward
Brownian motion in hiPSC-CMs in terms of long-term health,
adaptability and responsiveness to unpredictable stimuli.
Conclusions
In conclusion, the hiPSC-LQT-CMs appear to exhibit fractal-
like complexity at baseline condition suggesting that the intrin-
sic mechanisms of LQT-CMs contributing to the fractal com-
plexity are not altered. Although the effects of various com-
pounds to the field potential parameters were as expected, the
fractal-like complexity of the hiPSC-CMs was significantly al-
tered in healthy as well as LQT-specific CMs. No significant
differences in the α scaling exponent were found betweenWT-
and LQT-CMs. These findings may suggest that the cardiac ion
channel generating IKs current as well as the modulation of β1-
adrenoreceptors by β-blocker bisoprolol may contribute to the
fractal-like complexity of the hiPSC-CMs.
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